A diagnosis of cancer may be suspected based on history and physical examination but requires confirmation by biopsy and histopathologic examination. Sometimes the first indication is an abnormal laboratory test result (eg, anemia resulting from colon cancer).
A complete history and physical examination may reveal unexpected clues to early cancer.
(See also Overview of Cancer.)
History
Physicians must be aware of predisposing factors and must specifically ask about familial cancers, environmental exposures (including smoking history), and prior or present illnesses (eg, autoimmune disorders, previous immune-suppressing therapy, hepatitis B or hepatitis C infection, HIV infection, abnormal Papanicolaou test, human papillomavirus infection).
Symptoms suggesting occult cancer can include
Fatigue
Weight loss
Fevers
Night sweats
Cough
Hemoptysis
Hematemesis
Hematochezia
Change in bowel habits
Persistent pain
Other symptoms may be present depending on the site of cancer (eg, hoarseness in laryngeal cancer or abnormal vaginal bleeding in uterine cancer).
Physical examination
Particular attention should be paid to skin, lymph nodes, lungs, breasts, abdomen, and testes. Prostate, rectal, and vaginal examinations are also important. Findings help direct further testing, including x-rays and biopsies.
Testing
Tests include imaging tests, biomarkers, and biopsies; one or more of which may be indicated in patients with a suggestive history or physical or laboratory findings.
Imaging tests include plain x-rays, ultrasonography, CT, positron emission tomography (PET), and MRI studies. These tests assist in identifying abnormalities, determining qualities of a mass (solid or cystic), providing dimensions, and establishing relationship to surrounding structures, which may be important if surgery or biopsy is being considered.
Biomarkers may offer corroborating evidence in patients with findings suggestive of a specific cancer (see Tumor Immunodiagnosis). Most are not used as routine screening tests, except in high-risk patients. Useful examples include
Alpha-fetoprotein (hepatocellular carcinoma, testicular carcinoma)
Carcinoembryonic antigen (colon cancer)
Serum immunoglobulins (multiple myeloma)
Molecular tests (diverse cancers)
CA 125 (ovarian cancer)
CA 27-29 (breast cancer)
PSA (prostate-specific antigen—prostate cancer)
Some of these biomarkers may be most useful in monitoring the response to treatment rather than in tumor detection.
Biopsy to confirm the diagnosis and tissue of origin is almost always required when cancer is suspected. The choice of biopsy site is usually determined by ease of access and degree of invasiveness. If lymphadenopathy is present, fine-needle or core biopsy may reveal the cancer type. Core biopsies or lymph node excision are recommended for diagnosis of lymphomas because preservation of nodal architecture is important for accurate histologic diagnosis. Sometimes an open biopsy is needed. Other biopsy routes include bronchoscopy or mediastinoscopy for easily accessible mediastinal or central pulmonary tumors, percutaneous liver biopsy if liver lesions are present, and CT- or ultrasound-guided biopsy of lung or soft tissue masses.
Grading is a histologic measure of cancer aggressiveness and provides important prognostic information. It is determined by examining the tissue specimen. Grade is based on the morphologic appearance of cancer cells, including the appearance of the nuclei, cytoplasm, and nucleoli; frequency of mitoses; and amount of necrosis. For many cancers, grading scales have been developed.
Molecular tests such as chromosomal analysis, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), and cell surface antigen testing (eg, in lymphomas, leukemias, lung, and gastrointestinal cancers) help delineate the origin of metastatic cancers, particularly for cancers of unknown primary origin, and may be helpful in selecting therapy.
Staging
Once a histologic diagnosis is made, staging (ie, determination of the extent of disease) helps in treatment decision-making and influences prognosis. Clinical staging uses data from the history, physical examination, imaging tests, laboratory tests, and biopsy of bone marrow, lymph nodes, or other sites of suspected disease. For staging of specific neoplasms, see details in the organ-relevant discussion.
Imaging tests
Imaging tests, especially CT, PET, and MRI, can detect metastases to brain, lungs, or abdomen, including the adrenal glands, retroperitoneal lymph nodes, liver, and spleen. MRI (with gadolinium contrast) is the procedure of choice for recognition and evaluation of brain cancers, primary and metastatic. PET scanning is increasingly being used to determine the metabolic activity of a suspect lymph node, lung nodule, or other mass. Integrated PET–CT can be valuable, especially in lung, head and neck, and breast cancer and in lymphoma.
Ultrasonography can be used to study breast, ovarian, orbital, thyroid, cardiac, pericardial, hepatic, pancreatic, renal, testicular, and retroperitoneal masses. It may help guide percutaneous biopsies and differentiate fluid-filled cysts from solid masses.
Nuclear scans can identify several types of metastases (eg, thyroid cancer). Bone scans identify abnormal bone growth (ie, osteoblastic activity) before it is visible on plain x-ray. Thus, bone scans are useless in neoplasms that are purely lytic (eg, multiple myeloma); routine bone x-rays are the study of choice in such diseases.
Laboratory tests
Invasive tests
Mediastinoscopy is especially valuable in the staging of non–small cell lung cancer. When mediastinal lymph node involvement is found, patients may benefit from pre-surgery chemotherapy and/or radiation therapy.
Bone marrow aspiration and biopsy are especially useful in detecting involvement by leukemias, lymphomas, and plasma cell myeloma (multiple myeloma) and metastases from small cell lung, breast, and prostate cancers. Bone marrow biopsy may be informative in patients with unexplained hematologic abnormalities (ie, anemia, thrombocytopenia, pancytopenia).
Biopsy of sentinel regional lymph nodes is part of the evaluation of many cancers, such as breast, thyroid, gastric, lung, and colon cancers and melanoma. Removal of a sentinel lymph node (as defined by uptake of contrast or radioactivity injected into the cancer) may allow limited but definitive lymph node sampling in patients with these cancers.
